DNLI Stock Analysis Today
Updated Nov 7, 2026 · trends, key levels, insider activity and news
Is DNLI bullish or bearish today?
Daily trend: Uptrend (starting) — turns down below $17.33
SEPT signal: Institutional Drive · Consolidating
Research grade: B · fair value $23.17 (+73.6%)
DNLI trend by timeframe
| Daily | Uptrend (starting) |
|---|---|
| 4 hour | Expanding |
| 1 hour | Strong Bullish |
| 15 min | Descending Triangle |
| 5 min | Ascending Triangle |
Trends are calculated from price structure and update during market hours.
DNLI support and resistance levels
Resistance (above)
$21.269 touches
$22.632 touches
$24.204 touches
Support (below)
$19.7810 touches
$18.3216 touches
$17.333 touches
Upside zones: $23.41 / $24.02 / $24.63
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 230-day net
—Hedge fund holders
255Latest DNLI news and filings
- AnalystBenzinga
Morgan Stanley keeps Overweight on Denali Therapeutics, lifts target to $42
Morgan Stanley stayed positive on Denali Therapeutics and raised its price target to $42. The Overweight rating means the firm still expects the stock to outperform.
- AnalystBenzinga
Wedbush keeps Outperform rating on Denali Therapeutics, lifts target to $24
Wedbush reiterated an Outperform rating on Denali Therapeutics and raised its price target to $24. The change reflects the firm's updated view on the stock.
- AnalystFiscal.ai
Wedbush lifts Denali Therapeutics target to $24 from $23
An analyst at Wedbush raised the firm's valuation level for Denali Therapeutics by one dollar, moving it to $24. The update concerns the biotech company's stock outlook.
- AnalystBenzinga
BTIG keeps Buy rating on Denali Therapeutics with $39 target
BTIG repeated its Buy call on Denali Therapeutics and left its $39 price target unchanged. The note restates the firm's existing view on the biotech stock.
- EarningsFiscal.ai
Denali Therapeutics Posts Q3 2026 Financials
The biotech company released its quarterly financial figures for the three months ended in 2026. The filing covers its latest period results.
- EarningsBenzinga
Denali Therapeutics holds Q3 2026 earnings call
Denali Therapeutics discussed its third-quarter 2026 results during an earnings call. The transcript covers the company's quarterly performance.
- GuidanceBenzinga
Denali Therapeutics guides Q4 sales to $30M-$32M, above $22.659M estimate
Denali Therapeutics said it expects fourth-quarter sales of $30 million to $32 million. That range is higher than the $22.659 million estimate.
- ProductBenzinga
Denali says zafinofusp alfa Phase 1/2 trial in Sanfilippo syndrome finished primary endpoint treatment period
Denali reported that the primary endpoint treatment period of its Phase 1/2 study of zafinofusp alfa in Sanfilippo syndrome is complete. Data from the trial are expected in the first quarter of 2027.
- EarningsBenzinga
Denali Therapeutics posts $0.37 per-share profit, revenue of $17.778M for third quarter
The biotech company's quarterly profit and revenue both came in above analyst expectations. It earned $0.37 a share on $17.778 million in sales.
Live DNLI chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Is DNLI bullish or bearish today?
DNLI daily trend: Uptrend (starting) — turns down below $17.33. SEPT signal: Institutional Drive (Consolidating). Updated Nov 7, 2026.
What is DNLI's trend on each timeframe?
Daily: Uptrend (starting); 4 hour: Expanding; 1 hour: Strong Bullish; 15 min: Descending Triangle; 5 min: Ascending Triangle.
What are DNLI support and resistance levels?
Support: $19.78, $18.32, $17.33. Resistance: $21.26, $22.63, $24.20. Last price $20.07.
Are insiders buying or selling DNLI?
Insider signal: Sell. Last 30 days: 0 buys, 2 sells. 255 hedge funds hold DNLI.
What is the latest news on DNLI?
Nov 4, 2026: Morgan Stanley keeps Overweight on Denali Therapeutics, lifts target to $42 · Nov 4, 2026: Wedbush keeps Outperform rating on Denali Therapeutics, lifts target to $24 · Nov 4, 2026: Wedbush lifts Denali Therapeutics target to $24 from $23